A woman with curly gray hair and glasses smiling, wearing a striped shirt and a colorful necklace.

Suzanne Ostrand-Rosenberg, PhD

Languages spoken: English

Academic Information

Departments Adjunct - Pathology

Selected Publications

Journal Article

  1. Geis-Asteggiante L, Ostrand-Rosenberg S, Fenselau C, Edwards N (2016). Evaluation of Spectral Counting for Relative Quantitation of Proteoforms in Top-Down Proteomics. Analytical chemistry, 88(22), 10900-10907.
  2. Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg (2011). Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood, 117(20), 5381-90.
  3. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg (2010). Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer research, 70(1), 68-77.
  4. Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, Qi (2011). Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. The Journal of biological chemistry, 286(26), 23591-9.
  5. Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg (2011). Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. Journal of immunology (Baltimore, Md., 186(12), 6822-9.
  6. Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg (2013). Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. Journal of immunology (Baltimore, Md., 191(5), 2829-36.
  7. Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg (2014). Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. Journal of leukocyte biology, 96(6), 1109-18.
  8. Parker KH, Horn LA, Ostrand-Rosenberg (2016). High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy. Journal of leukocyte biology, 100(3), 463-70.
  9. Ostrand-Rosenberg S, Sinha P, Figley C, Long R, Park D, Carter D, Clements V (2017). Frontline Science: Myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice. Journal of leukocyte biology, 101(5), 1091-1101.
  10. Clements VK, Long T, Long R, Figley C, Smith DMC, Ostrand-Rosenberg (2018). Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells. Journal of leukocyte biology, 103(3), 395-407.
  11. Chornoguz O, Grmai L, Sinha P, Artemenko KA, Zubarev RA, Ostrand-Rosenberg (2011). Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Molecular & cellular proteomics, 10(3), M110.002980.
  12. Burke M, Choksawangkarn W, Edwards N, Ostrand-Rosenberg S, Fenselau (2014). Exosomes from myeloid-derived suppressor cells carry biologically active proteins. Journal of proteome research, 13(2), 836-43.
  13. Chauhan S, Danielson S, Clements V, Edwards N, Ostrand-Rosenberg S, Fenselau (2017). Surface Glycoproteins of Exosomes Shed by Myeloid-Derived Suppressor Cells Contribute to Function. Journal of proteome research, 16(1), 238-246.
  14. Adams KR, Chauhan S, Patel DB, Clements VK, Wang Y, Jay SM, Edwards NJ, Ostrand-Rosenberg S, Fenselau (2018). Ubiquitin Conjugation Probed by Inflammation in Myeloid-Derived Suppressor Cell Extracellular Vesicles. Journal of proteome research, 17(1), 315-324.
  15. Geis-Asteggiante L, Belew AT, Clements VK, Edwards NJ, Ostrand-Rosenberg S, El-Sayed NM, Fenselau (2018). Differential Content of Proteins, mRNAs, and miRNAs Suggests that MDSC and Their Exosomes May Mediate Distinct Immune Suppressive Functions. Journal of proteome research, 17(1), 486-498.
  16. Horn LA, Ciavattone NG, Atkinson R, Woldergerima N, Wolf J, Clements VK, Sinha P, Poudel M, Ostrand-Rosenberg (2017). CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget, 8(35), 57964-57980.
  17. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller A (2012). IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer discovery, 2(8), 722-35.
  18. Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, Ostrand-Rosenberg S, Abrams SI, Evans S (2016). Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.LID - 10.7554/eLife.17375 [doi]LID - e17375 [pii]. eLife, 5,
  19. Haile ST, Horn LA, Ostrand-Rosenberg (2014). A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. Cancer immunology research, 2(7), 610-5.
  20. Horn LA, Long TM, Atkinson R, Clements V, Ostrand-Rosenberg (2018). Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. Cancer immunology research, 6(1), 59-68.

Review

  1. Parker KH, Beury DW, Ostrand-Rosenberg S (2015). Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. [Review]. Adv Cancer Res, 128, 95-139.
  2. Ostrand-Rosenberg (2018). Myeloid derived-suppressor cells: their role in cancer and obesity. Current opinion in immunology, 51, 68-75.
  3. Ostrand-Rosenberg S, Horn LA, Haile S (2014). The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. Journal of immunology (Baltimore, Md., 193(8), 3835-41.
  4. Ostrand-Rosenberg S, Fenselau (2018). Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment. Journal of immunology (Baltimore, Md., 200(2), 422-431.
  5. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel M (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature medicine, 24(5), 541-550.
  6. Gabrilovich DI, Ostrand-Rosenberg S, Bronte (2012). Coordinated regulation of myeloid cells by tumours. Nature reviews. Immunology, 12(4), 253-68.
  7. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich D (2016). Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature communications, 7, 12150.